Montelukast modifies simvastatin‐induced myopathy and hepatotoxicity
- 6 August 2019
- journal article
- research article
- Published by Wiley in Drug Development Research
- Vol. 80 (7), 1000-1009
- https://doi.org/10.1002/ddr.21581
Abstract
Montelukast (MNK) has prominent anti-inflammatory and antioxidant activities. It can protect the liver in different hepatotoxic models in animals. Simvastatin (SMV) is one of commonly used lipid lowering drugs for treatment of dyslipidemia in order to reduce cardiovascular disease. It has severe side effects such as myopathy and hepatotoxicity. The aim of the present study is to investigate the possible effect of MNK on SMV-induced myopathy and hepatotoxicity. Four groups of male rats: control group which received saline via stomach tube, MNK treated group (received 10 mg/kg/day MNK via stomach tube), SMV treated group (received 30 mg/kg/day SMV via stomach tube), and MNK + SMV (combination) group which received both MNK and SMV. All animals were treated for 14 days before obtaining blood and tissue samples. SMV has both hepatotoxic effects and myopathy. SMV caused a significant increase in myoglobin, creatinine kinase, ALT, AST, ALP, and bilirubin but, it decreased total proteins, globulin and albumin levels. Co-treatment of SMV and MNK increased the antioxidant activity significantly. MNK modifies partially the myopathic changes and hepatotoxic effect of SMV. Co-administration of MNK and SMV decreased their toxic potentials on the liver, skeletal muscles, and kidney. They have antioxidant activities when given together that produce muscle and hepatic protective effects.Keywords
This publication has 34 references indexed in Scilit:
- Protective Effect of Montelukast Which Is Cysteinyl-Leukotriene Receptor Antagonist on Gentamicin-Induced Nephrotoxicity and Oxidative Damage in Rat KidneyRenal Failure, 2013
- Montelukast ameliorates kidney function and urinary bladder sensitivity in experimentally induced renal dysfunction in ratsFundamental & Clinical Pharmacology, 2011
- Montelukast, a leukotriene receptor antagonist abrogates lipopolysaccharide-induced toxicity and oxidative stress in rat liverPathophysiology, 2011
- Montelukast induced acute hepatocellular liver injuryJournal of Postgraduate Medicine, 2009
- Renal Protective Effects of Leukotriene Receptor Blockers in an Experimental Model of Cyclosporine NephrotoxicityTransplantation Proceedings, 2008
- Fatal liver failure following food supplements during chronic treatment with montelukastDigestive and Liver Disease, 2007
- Clinical Pattern of Zileuton-Associated Liver InjuryDrug Safety, 2007
- Liver transplantation for acute liver failure from drug induced liver injury in the United StatesLiver Transplantation, 2004
- A review of montelukast in the treatment of asthma and allergic rhinitisExpert Opinion on Pharmacotherapy, 2004
- Tissue sulfhydryl groupsArchives of Biochemistry and Biophysics, 1959